Avidity: A New Approach to Exon Skipping

April 27, 2022 1:00PM

Join Jett Foundation’s Community Webinar Series as we welcome Kelly DiTrapani, Mark Stahl, and Alissa Peters from Avidity Biosciences for a presentation and discussion on a new approach to exon skipping. Avidity plans to advance their first drug development program for Duchenne muscular dystrophy, AOC 1044, into clinical trials by the end of this year.

Guest Speakers

Kelly DiTrapani Headshot

Kelly DiTrapani, RN, BSN, BA
Vice President, Medical Affairs
Avidity Biosciences

In September of 2020, Kelly DiTrapani joined Avidity as Vice President of Medical Affairs at Avidity Biosciences. Kelly brings extensive commercial and medical affairs leadership in the life sciences industry, focused on bringing innovative therapeutics to patients in the oncology and rare disease spaces including Gleevec, Soliris, and Imbruvica. Throughout her career, Kelly has held positions in industries and academics across roles in research, commercial, and medical affairs at Ortho Biotech (J&J), Novartis Oncology, Duke University, Alexion Pharmaceuticals, Pharmacyclics, Versartis and Iovance Biotherapeutics. Kelly received both her Bachelor of Arts and Bachelor of Science in Nursing from Duke University. Visit Kelly on LinkedIn.

Mark Stahl Headshot

Mark Stahl, MD, PHD
Senior Director, Clinical Development
Avidity Biosciences

Mark Stahl joined Avidity as Senior Medical Director in March of 2021. Most recently, he served as Medical Director in Early Clinical Development at Neurocrine Biosciences, where he worked on multiple pre-clinical and clinical stage programs, including the initiation of new gene therapy programs in rare diseases. Previously, Mark worked as an Assistant Professor at Penn State University, where he founded a research laboratory focused on modeling neurodegenerative diseases, was associate director of the university’s Medical Scientist Training Program, and maintained an active clinical practice in neurology. Mark holds a M.D. degree from the Albert Einstein College of Medicine and completed both residency in neurology and fellowship training in movement disorders at UCLA. He holds a Ph.D. in cell biology, also from the Albert Einstein College of Medicine, and completed his postdoctoral research fellowship training in neuroscience at UCLA. Visit Mark on LinkedIn.

Alissa Peters Headshot

Alissa Peters
Director of Patient Advocacy and Corporate Affairs
Avidity Biosciences

Alissa joined Avidity Biosciences in June of 2020 and serves as the Director of Patient Advocacy and Corporate Affairs. Alissa has focused her career on supporting the development and commercialization of RNA-targeted therapeutics for rare diseases with high unmet needs. Prior to joining Avidity, Alissa served as Associate Director of Global Marketing, helping bring Tegsedi® to patients living with TTR Amyloidosis with Polyneuropathy, a rare neuromuscular disease which ignited her passion to focus in this therapeutic area. At Avidity, Alissa actively partners with patient and advocacy communities to ensure their perspectives are central across all initiatives at the organization. Alissa is passionate about seeing people’s lives changed through the delivery of new therapeutics. Visit Alissa on LinkedIn.

Community Webinar Series - Better preparing for challenges in Duchenne

Our Community Webinar Series is focused on ensuring that our Duchenne community is better prepared for those unexpected moments, challenging medical decisions, and difficult stages when on a Duchenne journey.

No one ever expects Duchenne and there is no correct way to tackle a diagnosis, but we can always better prepare. This webinar series is an opportunity to equip yourself with more knowledge, resources, and tools for those real-life, often unanticipated, scenarios.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open